AZ, Amgen get speedy FDA review for asthma drug tezepelumab

The FDA has started a priority review of AstraZeneca and Amgen's severe asthma antibody tezepelumab, setting a date for a decision in the first quarter of 2022.

AZ trumpets tezepelumab data as filing for severe asthma loo...

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than riv

AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial

AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail

EU clears GSK’s asthma drug Nucala in patient-friendly forma...

Sanofi/Regeneron asthma trial casts doubt on IL-33 class pro...

Breakthrough designation AstraZeneca's severe asthma drug

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough de